compounding glp-1 enforcement news Out of Shortage, Into Controversy: The Fight Over GLP-1 News for 2026: New

Participants included adults who had been using GLP-1 for at least three months

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Conclusions Hypomorphic PAM T2D-risk alleles reduce amidating enzyme activity, elevate circulating GLP-1 levels, and impair GLP-1 post-receptor signaling, culminating in a selective and clinically meaningful reduction in GLP-1RA efficacy

Key players in Chiles GLP-1 segment: Novo Nordisk Market leader with Ozempic, Victoza, and Wegovy Eli Lilly Bringing innovation with Mounjaro (Tirzepatide) Sanofi Providing Soliqua, a GLP-1 + insulin combo CFR Pharmaceuticals (Abbott) Local affiliate with strong market access Biocon Expanding biosimilar reach in Latam AstraZeneca Strategic focus on metabolic & cardiovascular synergy With increasing physician adoption and patient demand, Chile is evolving into a high-opportunity market for obesity and type 2 diabetes therapies

Read the full paper at the link in the comments below